Cover Image
市場調查報告書

全球大腸癌症治療藥市場產品、開發平台分析:組合標靶治療和免疫學,朝向下個階段

Product and Pipeline Analysis of the Global Colorectal Cancer Market - Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level

出版商 Frost & Sullivan 商品編碼 339441
出版日期 內容資訊 英文 105 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球大腸癌症治療藥市場產品、開發平台分析:組合標靶治療和免疫學,朝向下個階段 Product and Pipeline Analysis of the Global Colorectal Cancer Market - Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level
出版日期: 2015年09月09日 內容資訊: 英文 105 Pages
簡介

本報告提供全球大腸癌症 (CRC) 治療藥市場相關調查分析、市場概要、收益預測、競爭情形、上市產品、開發平台藥物分析、最近的認證的核可藥、後期開發平台藥物候補等相關的系統性資訊。

第1章 摘要整理

第2章 調查手法和範圍

第3章 市場概要

  • 市場概要:治療的種類 (開發中)
  • 市場概要:全球CRC的發病率
  • 市場概要:美國的發病率:各年齡,性別
  • 市場概要:生物標記的種類區分
  • 市場概要:主要的M&A,夥伴關係
  • 市場概要:最近的發展趨勢

第4章 收益預測

  • 全球CRC市場:收益預測
  • 收益預測的考察

第5章 競爭情形

  • 競爭情形概要
  • 競爭情形:從階段3到銷售
  • 競爭情形:階段2
  • 競爭情形:階段1

第6章 上市產品

  • 主要上市產品

第7章 開發平台藥物分析

  • 開發平台概要:階段3
  • 開發平台概要:階段2
  • 開發平台概要:階段1
  • 競爭情形:樞紐試驗 (階段3)
  • 主要活動的時間軸
  • 專利失效
  • 開發平台的考察

第8章 最近認證的核可藥、後期開發平台藥物候補的產品開發動態即時看板系統

  • 產品開發動態即時看板系統 - Avastin (Bevacizumab) :Genentech Inc. (Roche Group)
  • 產品開發動態即時看板系統 - BBI503:Boston Biomedical
  • 產品開發動態即時看板系統 - Cyramza (ramicirumab):Eli Lilly
  • 產品開發動態即時看板系統 - Erbitux (cetuximab):Eli Lilly/BMS/Merck
  • 產品開發動態即時看板系統 - Imprime PGG:Biothera
  • 產品開發動態即時看板系統 - Lonsurf (TAS-102):大鵬藥品 (大塚製藥)
  • 產品開發動態即時看板系統 - MGN1703:Mologen
  • 產品開發動態即時看板系統 - Nintedanib (BIBF-1120,OFEV):Boehringer Ingelheim
  • 產品開發動態即時看板系統 - Stivarga (regorafenib):Bayer/Onyx Pharmaceuticals
  • 產品開發動態即時看板系統 - Zaltrap (aflibercept):Sanofi

第9章 結論

第10章 關於Frost&Sullivan

目錄
Product Code: M986-01-00-00-00

Research Overview

This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:

  • targeted therapies
  • cytotoxics
  • cancer vaccines
  • other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).

The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.

Market Overview

Strong drug pipeline continues to expand

The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.

Colorectal cancer care edges toward personalisation

With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).

Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Executive Summary (continued)
  • 4. Executive Summary (continued)
  • 5. Executive Summary (continued)
  • 6. Physician Treatment Guidelines-Lines of Therapy
  • 7. Key Trends
  • 8. Market Opportunities
  • 9. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. MARKET OVERVIEW

Market Overview

  • 1. Market Overview-Types of Treatment in Development
  • 2. Market Overview-Global Incidences of CRC
  • 3. Market Overview-US Incidence Rates by Year and Sex
  • 4. Market Overview-Biomarker Type Segmentation
  • 5. Market Overview-Key Mergers, Acquisitions, and Partnerships
  • 6. Market Overview-Recent Developments

4. REVENUE FORECAST

Revenue Forecast

  • 1. Global CRC Market-Revenue Forecast
  • 2. Revenue Forecast Discussion
  • 3. Revenue Forecast Discussion (continued)
  • 4. Revenue Forecast Discussion (continued)

5. COMPETITIVE LANDSCAPE

Competitive Landscape

  • 1. Competitive Landscape Overview
  • 2. Competitive Landscape-Phase III to Launch
  • 3. Competitive Landscape-Phase II
  • 4. Competitive Landscape-Phase I

6. MARKETED PRODUCTS

Marketed Products

  • 1. Key Marketed Products
  • 2. Key Marketed Products (continued)
  • 3. Key Marketed Products (continued)
  • 4. Key Marketed Products (continued)

7. PIPELINE DRUGS ANALYSIS

Pipeline Drugs Analysis

  • 1. Pipeline Synopsis-Phase III
  • 2. Pipeline Synopsis-Phase III (continued)
  • 3. Pipeline Synopsis-Phase III (continued)
  • 4. Pipeline Synopsis-Phase III (continued)
  • 5. Pipeline Synopsis-Phase III (continued)
  • 6. Pipeline Synopsis-Phase II
  • 7. Pipeline Synopsis-Phase II (continued)
  • 8. Pipeline Synopsis-Phase II (continued)
  • 9. Pipeline Synopsis-Phase II (continued)
  • 10. Pipeline Synopsis-Phase II (continued)
  • 11. Pipeline Synopsis-Phase II (continued)
  • 12. Pipeline Synopsis-Phase II (continued)
  • 13. Pipeline Synopsis-Phase II (continued)
  • 14. Pipeline Synopsis-Phase II (continued)
  • 15. Pipeline Synopsis-Phase II (continued)
  • 16. Pipeline Synopsis-Phase II (continued)
  • 17. Pipeline Synopsis-Phase II (continued)
  • 18. Pipeline Synopsis-Phase II (continued)
  • 19. Pipeline Synopsis-Phase II (continued)
  • 20. Pipeline Synopsis-Phase I
  • 21. Pipeline Synopsis-Phase I (continued)
  • 22. Pipeline Synopsis-Phase I (continued)
  • 23. Pipeline Synopsis-Phase I (continued)
  • 24. Pipeline Synopsis-Phase I (continued)
  • 25. Pipeline Synopsis-Phase I (continued)
  • 26. Competitive Landscape-Pivotal Phase III Trials
  • 27. Timeline of Key Events
  • 28. Patent Expirations
  • 29. Pipeline Discussion
  • 30. Pipeline Discussion (continued)

8. PRODUCT DASHBOARD OF RECENTLY APPROVED DRUGS AND LATE-STAGE PIPELINE DRUG CANDIDATES

Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug Candidates

  • 1. Product Dashboard: Avastin (Bevacizumab)-Genentech Inc. (Roche Group)
  • 2. Avastin (Genentech, Roche)-SWOT Analysis
  • 3. Product Dashboard-BBI503: Boston Biomedical
  • 4. BBI503 (Boston Biomedical)-SWOT Analysis
  • 5. Product Dashboard-Cyramza (ramicirumab): Eli Lilly
  • 6. Cyramza (ramicirumab) (Eli Lilly)-SWOT Analysis
  • 7. Product Dashboard-Erbitux (cetuximab): Eli Lilly/BMS/Merck
  • 8. Erbitux (Eli Lilly, BMS, and Merck)-SWOT Analysis
  • 9. Product Dashboard-Imprime PGG: Biothera
  • 10. Imprime PGG (Biothera)-SWOT Analysis
  • 11. Product Dashboard-Lonsurf (TAS-102): Taiho (Otsuka)
  • 12. Lonsurf (TAS-102) (Taiho, Otsuka)-SWOT Analysis
  • 13. Product Dashboard-MGN1703: Mologen
  • 14. MGN1703 (Mologen)-SWOT Analysis
  • 15. Product Dashboard-Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim
  • 16. Nintedanib (BIBF-1120, OFEV) (BI)-SWOT Analysis
  • 17. Product Dashboard-Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals
  • 18. Stivarga (Bayer, Onyx)-SWOT Analysis
  • 19. Product Dashboard-Zaltrap (aflibercept): Sanofi
  • 20. Zaltrap (aflibercept) (Sanofi)-SWOT Analysis

9. CONCLUSIONS

Conclusions

  • 1. Conclusions
  • 2. Conclusions (continued)
  • 3. The Last Word-3 Big Predictions
  • 4. The Last Word-Discussion
  • 5. Legal Disclaimer

10. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top